Floatz logo

Tilmanocept

NASH - Nonalcoholic Steatohepatitis

Navidea BiopharmaceuticalsOtherPhase 1Dormant
CC
42/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
27/ 100
Competitive Position
89/ 100

Competitive context

24 Active assets in the NASH - Nonalcoholic Steatohepatitis cohort.

Asset / SponsorPhaseRating
Empagliflozin
Badr University
Phase 4BBB
Lipitor
Badr University
Phase 4BB
Sitagliptin
NeuroBo Pharmaceuticals Inc.
Phase 4BB
Aldafermin
NGM Biopharmaceuticals, Inc
Phase 2BB
DULAGLUTIDE
Central Hospital, Nancy, France
Phase 4BB

View all 50 →

Same molecule, other indications

Tilmanocept is also rated in:

melanomaDormant
B
Indicative ·
61 / 100
View asset →
Sentinel Lymph Node BiopsyDormant
B
Indicative ·
56 / 100
View asset →
Sentinel Lymph NodeDormant
B
Indicative ·
56 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →